Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Neuropsychiatric disorders

The choice of antipsychotics in schizophrenia

Nature Reviews Neurology volume 5, pages 308–310 (2009)Cite this article

In light of claims of improved efficacy and lower incidence of adverse effects compared with older drugs, second-generation antipsychotics have emerged as the predominant treatment for schizophrenia. A new meta-analysis concludes that the difference in efficacy between newer and older agents is small, and the current classification scheme for antipsychotics does not survive close scrutiny.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Leucht, S. et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373, 31–41 (2009).

    Article  CAS  Google Scholar 

  2. Gründer, G., Hippius, H. & Carlsson, A. The 'atypicality' of antipsychotics: a concept re-examined and re-defined. Nat. Rev. Drug Discov. 8, 197–202 (2009).

    Article  Google Scholar 

  3. Lieberman, J. A. et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353, 1209–1223 (2005).

    Article  CAS  Google Scholar 

  4. McEvoy, J. P. et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am. J. Psychiatry 163, 600–610 (2006).

    Article  Google Scholar 

  5. Leucht, S. et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am. J. Psychiatry 166, 152–163 (2009).

    Article  Google Scholar 

  6. Rosenheck, R. et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 290, 2693–2702 (2003).

    Article  CAS  Google Scholar 

  7. Jones, P. B. et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch. Gen. Psychiatry 63, 1079–1087 (2006).

    Article  CAS  Google Scholar 

  8. Carpenter, W. T. & Buchanan, R. W. Lessons to take home from CATIE. Psychiatr. Serv. 59, 523–525 (2008).

    Article  Google Scholar 

  9. Ross, C. A., Margolis, R. L., Reading, S. A., Pletnikov, M. & Coyle, J. T. Neurobiology of schizophrenia. Neuron 52, 139–153 (2006).

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. R. L. MargolisJohns Hopkins Schizophrenia Program, Department of Psychiatry, Johns Hopkins University School of Medicine, CMSC 8–121, 600 N. Wolfe Street, Baltimore, MD 21287, USA rmargoli@jhmi.edu

Authors and Affiliations

  1. Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Russell L. Margolis

Authors
  1. Russell L. Margolis
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

R. L. Margolis is a consultant for AstraZeneca.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Margolis, R. The choice of antipsychotics in schizophrenia. Nat Rev Neurol 5, 308–310 (2009). https://doi.org/10.1038/nrneurol.2009.68

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2009.68

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing